WeVote
Log In

Bill

Bill

LD 604

An Act To Ensure Access To Concurrent Methadone Treatment And Intensive Outpatient Programs

132nd Legislature (2025-2026) Introduced by Joe Baldacci and 8 co-sponsors

Maine law now permits simultaneous methadone and intensive outpatient program enrollment to improve opioid addiction treatment outcomes by combining medication and behavioral therapies.

Died in Possession of the Senate when the Legislature adjourned Sine Die and was PLACED IN THE LEGISLATIVE FILES. (DEAD)
#access #substanceusedisorder #treatment
0
WeVote Research Nonpartisan
Bill Summary · LD 604

Legislative bill overview

LD 604 requires Maine to ensure that individuals can simultaneously access methadone treatment and intensive outpatient programs (IOPs) for substance use disorder, removing barriers that currently force patients to choose between these complementary services. The bill addresses a gap in addiction treatment policy where existing regulations or practices have prevented concurrent enrollment in both programs despite clinical evidence supporting their combined use.

Why is this important

Methadone maintenance and intensive outpatient counseling address different aspects of opioid addiction recovery—pharmacological stabilization and behavioral/psychological treatment respectively. Preventing concurrent access forces patients into suboptimal treatment choices and may reduce overall recovery outcomes. This policy directly affects individuals struggling with opioid addiction and the effectiveness of Maine's substance use disorder treatment system.

Potential points of contention

  • Implementation costs: Expanding concurrent treatment access may require additional funding for treatment providers, staff, and program coordination, raising budget concerns during a time of fiscal constraints
  • Program capacity and resource strain: Rural and under-resourced areas of Maine may lack sufficient IOP capacity to accommodate increased concurrent enrollment, limiting the bill's practical impact in some regions
  • Clinical oversight questions: Stakeholders may debate whether adequate safeguards exist to ensure concurrent treatment doesn't create drug-seeking vulnerabilities or complicate clinical monitoring, or conversely, whether restrictions on concurrent access are clinically justified

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.